FGFR1 and breast cancer: Recently, it was demonstrated that, in ER+ breast cancer cells, the activation of the FGFR1/3-STAT3 signaling pathway leads to resistance to the PI3K/mTOR inhibitor named NVP-BEZ235 [81].